These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 9918315)

  • 1. GVL and GVHD following the infusion of a limited number of donor CD3 cells in the therapy of leukaemia relapse after bone marrow transplantation.
    du Toit C; Novitzky N
    Eur J Haematol; 1999 Jan; 62(1):68-9. PubMed ID: 9918315
    [No Abstract]   [Full Text] [Related]  

  • 2. Kinetics of the graft-versus-leukemia response after donor leukocyte infusions for relapsed chronic myeloid leukemia after allogeneic bone marrow transplantation.
    Baurmann H; Nagel S; Binder T; Neubauer A; Siegert W; Huhn D
    Blood; 1998 Nov; 92(10):3582-90. PubMed ID: 9808551
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Salvage immunotherapy using donor leukocyte infusions as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation: efficacy and toxicity of a defined T-cell dose.
    Drobyski WR; Keever CA; Roth MS; Koethe S; Hanson G; McFadden P; Gottschall JL; Ash RC; van Tuinen P; Horowitz MM
    Blood; 1993 Oct; 82(8):2310-8. PubMed ID: 8400284
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Allogeneic cell-mediated immunotherapy using donor lymphocytes for prevention of relapse in patients treated with allogeneic bone marrow transplantation for hematological malignancies.
    Naparstek E; Nagler A; Or R; Kapelushnik J; Slavin S
    Clin Transpl; 1996; ():281-90. PubMed ID: 9286578
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Donor leukocyte infusions for recurrent hematologic malignancies after allogeneic bone marrow transplantation: impact of infused and residual donor T cells.
    Verdonck LF; Petersen EJ; Lokhorst HM; Nieuwenhuis HK; Dekker AW; Tilanus MG; de Weger RA
    Bone Marrow Transplant; 1998 Dec; 22(11):1057-63. PubMed ID: 9877267
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relationship between graft-versus-host disease and graft-versus-leukaemia in partial T cell-depleted bone marrow transplantation.
    van der Straaten HM; Fijnheer R; Dekker AW; Nieuwenhuis HK; Verdonck LF
    Br J Haematol; 2001 Jul; 114(1):31-5. PubMed ID: 11472341
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adoptive immunotherapy following allogeneic bone marrow transplantation.
    Dazzi F; Goldman JM
    Annu Rev Med; 1998; 49():329-40. PubMed ID: 9509267
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adoptive immunotherapy using donor leukocytes following bone marrow transplantation for chronic myeloid leukemia: is T cell dose important in determining biological response?
    Mackinnon S; Papadopoulos EB; Carabasi MH; Reich L; Collins NH; O'Reilly RJ
    Bone Marrow Transplant; 1995 Apr; 15(4):591-4. PubMed ID: 7655386
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Survival in first or second remission after lymphocyte-depleted transplantation for Philadelphia chromosome-positive CML in first chronic phase.
    Schattenberg A; Preijers F; Mensink E; Bär B; Schaap N; Geurts van Kessel A; van der Maazen R; de Witte T
    Bone Marrow Transplant; 1997 Jun; 19(12):1205-12. PubMed ID: 9208114
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bone marrow transplantation depleted of T cells followed by repletion with incremental doses of donor lymphocytes for relapsing patients with chronic myeloid leukemia: a therapeutic strategy.
    Novitzky N; Rubinstein R; Hallett JM; du Toit CE; Thomas VL
    Transplantation; 2000 Apr; 69(7):1358-63. PubMed ID: 10798754
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Induction of graft-versus-host disease as immunotherapy for relapsed chronic myeloid leukemia.
    Porter DL; Roth MS; McGarigle C; Ferrara JL; Antin JH
    N Engl J Med; 1994 Jan; 330(2):100-6. PubMed ID: 8259165
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Cellular immunotherapy in chronic myeloid leukemia].
    Fernández MN
    Sangre (Barc); 1998 Apr; 43(2):164-70. PubMed ID: 9656778
    [No Abstract]   [Full Text] [Related]  

  • 13. Graft-versus-host disease following interferon therapy for relapsed chronic myeloid leukaemia post-allogeneic bone marrow transplantation.
    Browett PJ; Nelson J; Tiwari S; Van de Water NS; May S; Palmer SJ
    Bone Marrow Transplant; 1994 Oct; 14(4):641-4. PubMed ID: 7858542
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The highest leukaemia-free survival after allogeneic bone marrow transplantation is seen in patients with grade I acute graft-versus-host disease. Acute and Chronic Leukaemia Working Parties of the European Group for Blood and Marrow Transplantation (EBMT).
    Ringdén O; Hermans J; Labopin M; Apperley J; Gorin NC; Gratwohl A
    Leuk Lymphoma; 1996 Dec; 24(1-2):71-9. PubMed ID: 9049963
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Graft-versus-leukaemia.
    Barrett AJ; van Rhee F
    Baillieres Clin Haematol; 1997 Jun; 10(2):337-55. PubMed ID: 9376668
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bone marrow transplantation for patients with chronic myeloid leukaemia: T-cell depletion with Campath-1 reduces the incidence of graft-versus-host disease but may increase the risk of leukaemic relapse.
    Apperley JF; Jones L; Hale G; Waldmann H; Hows J; Rombos Y; Tsatalas C; Marcus RE; Goolden AW; Gordon-Smith EC
    Bone Marrow Transplant; 1986 May; 1(1):53-66. PubMed ID: 3332120
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Donor lymphocyte infusion followed by interferon-alpha plus low dose cyclosporine A for modulation of donor CD3 cells activity with monitoring of minimal residual disease and cellular chimerism in a patient with first hematologic relapse of chronic myelogenous leukemia after allogeneic bone marrow transplantation.
    Leda M; Ladon D; Pieczonka A; Boruczkowski D; Jólkowska J; Witt M; Wachowiak J
    Leuk Res; 2001 Apr; 25(4):353-7. PubMed ID: 11248334
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of mixed chimerism on graft-versus-host disease, disease recurrence and survival after HLA-identical marrow transplantation for aplastic anemia or chronic myelogenous leukemia.
    Huss R; Deeg HJ; Gooley T; Bryant E; Leisenring W; Clift R; Buckner CD; Martin P; Storb R; Appelbaum FR
    Bone Marrow Transplant; 1996 Oct; 18(4):767-76. PubMed ID: 8899193
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Allogeneic bone marrow transplantation for chronic myeloid leukemia using HLA identical sibling donors primed with G-CSF.
    Chen HR; Ji SQ; Wang HX; Yan HM
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2002 Aug; 10(4):340-6. PubMed ID: 12513770
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fatal graft-versus-host disease following HLA-mismatched donor lymphocyte infusion.
    Amrolia PJ; Rao K; Slater O; Ramsay A; Veys PA; Webb DK
    Bone Marrow Transplant; 2001 Sep; 28(6):623-5. PubMed ID: 11607779
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.